Cancer deaths from obesity have tripled in 20 years — which states have the highest and lowest rates
Cancer deaths tied to obesity have tripled in the US over the last two decades, according to sobering new research presented Sunday at the Endocrine Society's annual meeting in San Francisco, California.
The study analyzed more than 33,000 deaths from obesity-associated cancers between 1999 and 2020 and found that the age-adjusted mortality rate surged from 3.73 to 13.52 per million during that period — a more than threefold increase.
New research reveals a shocking uptick in obesity-related cancer deaths in the last two decades.
Louis-Photo – stock.adobe.com
The risk isn't spread evenly, either — women, older adults, black people, Native Americans and those living in rural areas bore the brunt of the deadly trend.
Geography also makes a big difference.
The new study found that Midwestern states had the highest rates of obesity-linked cancer deaths, while the Northeast fared the best.
At the state level, Vermont, Minnesota and Oklahoma saw the highest rates, while Utah, Alabama and Virginia had the lowest.
'Obesity is a significant risk factor for multiple cancers, contributing to significant mortality,' Dr. Faizan Ahmed of Hackensack Meridian Jersey Shore University Medical Center in Neptune City, NJ, said in a press release.
'This research underscores the need for targeted public health strategies such as early screening and improved access to care, especially in high-risk rural and underserved areas.'
Obesity now affects 40.3% of American adults, per CDC data.
grinny – stock.adobe.com
Obesity is strongly linked to at least 13 types of cancer, according to the Centers for Disease Control and Prevention (CDC).
These include cancers of the breast in postmenopausal women, colon, uterus, gallbladder, pancreas, liver, thyroid and even the brain, among others.
Together, these obesity-linked cancers account for a staggering 40% of all new cancer diagnoses in the US each year.
Obesity now affects 40.3% of American adults, per CDC data.
It is defined as having a body mass index of 30 or higher — and it is associated with an increased risk of sleep apnea, infertility, depression, heart disease, diabetes and certain cancers.
The World Health Organization officially declared obesity a global epidemic in 1997, noting that rates had nearly tripled since 1975 — which is when experts believe the epidemic began.
What has remained a hotly debated mystery is why the epidemic rages on, with many pointing the finger at lifestyle factors such as increases in ultra-processed foods and sedentary behavior.
The good news is that while technology may be making us fatter, TikTok nutrition hacks and trendy weight loss drugs offer novel ways to win the battle of the bulge.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
2 hours ago
- Yahoo
Vacuum Blood Collection Tube Market to Hit Valuation of US$ 4.40 Billion By 2033
The vacuum blood collection tube market experiences transformative growth driven by chronic disease management requirements, technological innovations enhancing specimen tracking, and strategic procurement consolidation, while addressing critical challenges in sample wastage reduction and sustainable material adoption across global healthcare networks. Chicago, July 14, 2025 (GLOBE NEWSWIRE) -- The global vacuum blood collection tube market was valued at US$ 3.24 billion in 2024 and is expected to reach US$ 4.40 billion by 2033, growing at a CAGR of 3.45% during the forecast period 2025–2033. Growing scrutiny by health authorities has made pre-analytical quality a boardroom issue, and that is resonating through the market. The European Union's IVDR, fully enforceable since May 2024, added 168 discrete General Safety and Performance Requirements that vacuum tube makers must document, resulting in a measurable surge in notified-body audit bookings. In the United States, the latest CLSI GP41-A7 guideline obliges laboratories to move away from open blood-draw systems, a shift echoed by recent College of American Pathologists accreditation checklists. China's NMPA simultaneously tightened bioburden limits, compelling domestic producers to requalify gamma-irradiation protocols. Collectively, these converging regulations are prompting hospital groups from Toronto to Taipei to rewrite supplier scorecards in favor of closed, traceable devices, directly underpinning purchase volumes in the vacuum blood collection tube market. Download a Free Sample to Preview the Report: Compliance expectations are translating into procurement mandates. India's CDSCO, for example, now requires a unique device identifier laser-etched on every tube sold to public hospitals, driving barcode-equipment orders by 32 percent in 2023-2024. Latin American reference labs have begun demanding tubes certified under ISO 6710:2022, an update that explicitly addresses hemolysis prevention. Because failed audit findings often trigger repeat testing, administrators calculate that each mislabeled specimen costs between US$ 200 and US$ 400 in avoidable downstream expenses. Consequently, supply contracts increasingly bundle staff training, quality documentation, and data-logging caps, turning what was once a commodity into a regulated, evidence-backed acquisition. This regulatory momentum is expected to keep the market on an upward compliance-driven trajectory through the rest of the decade. Key Findings in Vacuum Blood Collection Tube Market Market Forecast (2033) US$ 4.40 billion CAGR 3.45% Largest Region (2024) North America (36%) By Product Serum Tubes (32%) By Material Plastic (88%) By Application Routine Chemistry (28%) By Distribution Channel Direct Tender (46%) Top Drivers Fourteen billion annual clinical laboratory tests performed in United States Rising prevalence chronic disorders necessitating frequent blood monitoring procedures Increasing blood transfusions worldwide requiring specialized vacuum collection tubes Top Trends Smart tubes incorporating RFID tags enabling automated sample tracking Automation manufacturing processes producing over 500 million tubes annually Direct consumer diagnostic services expanding home blood collection markets Top Challenges FDA expanded medical device shortage list including collection tubes Tubes collect excess blood volumes causing significant sample wastage Complex disposal regulations varying across regions increasing operational costs Multiplex Diagnostics Boom Accelerates Color-Coded Tube Material Science Advancements Worldwide The explosive rise of syndromic test panels is reshaping workflow requirements inside clinical chemistry labs, pushing the vacuum blood collection tube market toward greater cap differentiation and additive precision. Between 2020 and 2024, the average number of distinct test panels processed daily by top U.S. reference labs climbed from 33 to 52, with many panels demanding paired serum and plasma samples. To prevent pre-analytical mix-ups, manufacturers expanded cap color assortments; SKU counts at three leading suppliers rose from 14 to 21 over the same period. Advanced pigments with higher spectral reflectance are enabling automated sorters to reach 99.98 percent cap recognition accuracy at belt speeds above 300 tubes per minute. Material science is also advancing faster. Newly commercialized bromobutyl rubber stoppers now exhibit sub-0.3 millimeter self-sealing diameters, minimizing aerosol generation during secondary access and aligning with National Institute for Occupational Safety and Health (NIOSH) guidelines. Concurrently, serum-separator gel chemistries have shifted toward thixotropic silicones that remain stable after 72-hour sample transport, critical for decentralized clinical trial logistics. Industry analysts cite these hardware innovations as a core driver behind the next wave of product launches in the vacuum blood collection tube market. The same trend is visible in Europe, where bundling agreements increasingly stipulate photometric transparency thresholds to facilitate optical-based clot detection in high-throughput analyzers, demonstrating how diagnostic complexity is exerting granular influence on tube design choices. Emerging Markets Modernize Phlebotomy Infrastructure Through Localized Procurement Strategies Today Public-sector modernization programs are filtering directly into purchasing behavior across emerging economies, strengthening regional importance within the vacuum blood collection tube market. Brazil's Unified Health System injected targeted capital to replace glass syringes with closed vacuum sets in 85 percent of tertiary hospitals by March 2024, cutting needlestick injuries by an estimated 41,000 incidents annually. Indonesia followed with a National Health Insurance procurement guideline that favors locally assembled PET tubes, enabling domestic output to triple within two years while reducing lead times from twelve to four weeks. Such localization satisfies both import-substitution policies and the need for just-in-time inventory amid exchange-rate volatility. These upgrades are paired with large-scale workforce training. Nigeria's Center for Disease Control certified 4,600 new phlebotomists on vacuum collection protocols in 2023 alone, supported by e-learning modules translated into Hausa and Yoruba. Meanwhile, India's Ayushman Bharat program includes digital dashboards that monitor per-capita blood-draw ratios state by state, offering granular consumption data previously unavailable to suppliers. For manufacturers, the implication is clear: product portfolios must accommodate tropical storage profiles, variable electricity reliability, and multilingual labeling. Companies that have co-invested in local molding and rubber-stopper lines report 27 percent lower logistics costs and faster regulatory clearances, strengthening competitive position within the vacuum blood collection tube market. Rapid Shift Toward Recyclable PET Vacuum Tube Bodies Reshaping Market Dynamics Healthcare systems are under pressure to cut carbon intensity, and that pressure now extends sharply into the vacuum blood collection tube market. Global hospitals generate an estimated nine million kilograms of plastic waste every day, prompting sustainability officers to target high-volume disposables first. Leading suppliers responded in 2024 with PET tube bodies weighing just 6.4 grams—about 30 percent lighter than legacy soda-lime glass alternatives—yet achieving identical vacuum retention for 18 months. The reduced resin mass translates to appreciable CO₂ savings; a 500-bed hospital switching entirely to the new format eliminates roughly 14 metric tons of annual transport emissions. Equally compelling are developments in circular packaging. Denmark's national procurement agency now awards up to 10 percent tender points for return-to-manufacturer recycling schemes that achieve a minimum 70 percent post-use material recovery rate. To comply, vendors embed near-infrared tracer pigments that allow facility-level sorters to distinguish between PET tube bodies and polyisoprene stoppers, thereby improving recycling yield without manual separation. Lifecycle assessments show the revised design cuts cradle-to-grave environmental impact scores by 38 points on the commonly used ReCiPe 2016 scale. These quantifiable, verifiable gains are quickly becoming negotiating leverage in the vacuum blood collection tube market, where environmentally conscious buyers increasingly link contract renewal to documented sustainability metrics rather than price alone. Automation Ready Racks and Robots Redefine High-Volume Blood Collection Workflows Clinical laboratories pursuing 'smart lab' status are re-engineering specimen flow, and automation-friendly packaging is now a decisive purchasing criterion within the vacuum blood collection tube market. More than 60 percent of large North American core labs commissioned track-based automation between 2021 and 2024, according to International Federation of Clinical Chemistry survey data. These systems insert tubes into driverless carts at speeds exceeding 500 units per hour, demanding consistently square-cut, burr-free rims to avoid jamming. Engineers therefore adopted precision injection-molding gates and optical inspection that can detect deviations as small as five microns, raising overall first-pass yield to 99.6 percent. Racks are evolving as well. The latest 50-well carriers feature RFID chips that log lot numbers and expiration dates, allowing middleware to quarantine expired stock automatically. When integrated with Athenahealth or EPIC LIS modules, sample-level traceability eliminates an average of 17 manual barcode scans per patient visit—saving nearly two minutes per draw and lowering ergonomic strain. As a result, capital equipment vendors include 'tube compatibility matrices' in bids, explicitly listing which brands guarantee uninterrupted conveyance. Diagnostics mega-labs now embed such matrices into supply contracts, edging out generic imports and channeling share toward innovation-oriented players in the vacuum blood collection tube market. Pandemic Aftermath Broadens Adoption of Decentralized Community Phlebotomy Service Models COVID-19 left a durable legacy: patients expect diagnostic services closer to home, and this preference reshapes volume flows inside the vacuum blood collection tube market. Across the United States, retail clinics inside pharmacies handled 78 million venipuncture episodes in 2023, up from 42 million pre-pandemic. Similar momentum emerged in Europe where the UK National Health Service funded 237 community phlebotomy hubs, each outfitted with messenger-tube logistics to nearby laboratories. Because these settings operate without the central vacuum manifolds common in hospitals, demand has shifted toward single-use, evacuated tubes with integrated safety needles and pre-attached holders. Mobile services are expanding even faster. India fielded more than 12,000 GPS-tracked phlebotomy vans by mid-2024; each vehicle carries miniature 4 °C compressors powered by rooftop solar panels, allowing specimens to remain within temperature range for eight hours. Such decentralized collection raises new technical considerations: tube wall strength must withstand vibration over unpaved roads, and printed labels must resist 95 percent relative humidity. Vendors meeting these criteria are enjoying higher reorder frequency, confirming decentralization as a structural, not transitory, growth vector for the vacuum blood collection tube market. As telehealth continues to drive at-home monitoring programs for oncology and chronic disease, tubes compatible with finger-prick micro-collection devices are expected to achieve double-digit unit growth, reinforcing the sector's post-pandemic evolution. Competitive Landscape Reconfigures As Cross-Border Manufacturing Alliances Become Mainstream Today Competitive dynamics within the market have pivoted sharply toward strategic alliances and technology licensing. Rather than erecting wholly owned plants, multinational brands are partnering with regional molders able to meet Class 8 clean-room standards in underused industrial parks. Southeast Asia saw eight such alliances inked in 2024, slashing lead times by 40 days compared with import models. In exchange, local partners receive access to proprietary coating chemistries that reduce platelet adhesion, elevating them from contract producers to innovation contributors. Private-label opportunities are also rising. U.S. group purchasing organizations awarded three-year contracts to hybrid manufacturers that blend European gel formulations with Latin American plastics, demonstrating how cross-border synergies win on both cost and performance. Meanwhile, corporate venture arms are seeding start-ups focused on AI-guided visual inspection; one Israeli firm claims its deep-learning camera systems catch 99.9 percent of micro-cracks at full production speed, a specification now referenced in three supply tenders. These maneuvers reveal a maturing but still fragmented competitive set in the vacuum blood collection tube market, where intellectual property, geographic proximity, and digital manufacturing are coalescing into a new success formula. Speak with a Subject Matter Expert Before You Decid: Digital Traceability and Predictive Analytics Define Future Procurement Decision Frameworks Digital transformation is moving from analyzers to consumables, and that shift is rewriting expectations across the vacuum blood collection tube market. Hospitals adopting RFID-enabled tubes report a 42 percent reduction in mislabeling events within 12 months, according to data collated by the U.S. Agency for Healthcare Research and Quality. Cloud dashboards aggregate scan data every five minutes, enabling inventory systems to flag impending stockouts seven days sooner than manual counts. The predictive edge is tangible: one Midwestern health network avoided an estimated US$ 1.2 million in courier overtime after algorithms diverted surplus tubes among its 18 sites before a winter storm. Regulators are taking notice. The U.S. FDA's Unique Device Identification final rule extension to Class I consumables, published in late 2024, means every evacuated tube must carry scannable production data by 2027. Forward-thinking suppliers are embedding QR codes printed with solvent-resistant inks that survive centrifugation at 5,000 g. Laboratories can therefore reconcile electronic medical record time stamps with centrifuge run logs, unlocking real-time chain-of-custody validation. As procurement committees increasingly rank suppliers by data interoperability, the vacuum blood collection tube market will likely reward vendors capable of bundling hardware, software, and analytics into cohesive, outcome-oriented solutions. The convergence of digital traceability and predictive analytics thus sets the stage for the industry's next competitive leap. Vacuum Blood Collection Tube Market Major Players: Advin Health Care AdvaCare Pharma Biota SEKISUI CHEMICAL CO., LTD. Becton, Dickinson and Company Cardinal Health Hindustan Syringes & Medical Devices Ltd Greiner AG MB Plastic Industries Other Prominent Players Key Segmentation: By Product Type Serum Tubes Plasma Separation Tubes Heparin Tubes EDTA Tubes Glucose Tubes ESR Tubes Others (Thrombin Tubes, Trace Element Tubes, etc.) By Material Plastic Glass By Application Routine Chemistry Blood Sugar Testing Coagulation Testing Lipid Profile Infectious Disease Testing Others By End User Hospitals Diagnostic Laboratories Blood Banks Ambulatory Surgical Centers Others (Academic Institutes, Research Labs) By Distribution Channel Direct Tender Retail Sales Online Sales Distributors By Region North America Europe Asia Pacific Middle East Africa South America Looking for Country-Level or Section-Wise Data? Customize This Report: About Astute Analytica Astute Analytica is a global market research and advisory firm providing data-driven insights across industries such as technology, healthcare, chemicals, semiconductors, FMCG, and more. We publish multiple reports daily, equipping businesses with the intelligence they need to navigate market trends, emerging opportunities, competitive landscapes, and technological advancements. With a team of experienced business analysts, economists, and industry experts, we deliver accurate, in-depth, and actionable research tailored to meet the strategic needs of our clients. At Astute Analytica, our clients come first, and we are committed to delivering cost-effective, high-value research solutions that drive success in an evolving marketplace. Contact Us:Astute AnalyticaPhone: +1-888 429 6757 (US Toll Free); +91-0120- 4483891 (Rest of the World)For Sales Enquiries: sales@ Follow us on: LinkedIn | Twitter | YouTube CONTACT: Contact Us: Astute Analytica Phone: +1-888 429 6757 (US Toll Free); +91-0120- 4483891 (Rest of the World) For Sales Enquiries: sales@ Website: in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Newsweek
5 hours ago
- Newsweek
Americans Told Not to Drink Coffee in 11 States
Based on facts, either observed and verified firsthand by the reporter, or reported and verified from knowledgeable sources. Newsweek AI is in beta. Translations may contain inaccuracies—please refer to the original content. Millions of Americans were told to cut out coffee as heat-related warnings took effect across 11 states on Monday, and the National Weather Service (NWS) predicted "dangerously hot conditions" in some parts of the U.S. The NWS advised avoiding drinking alcohol and caffeine, which can speed up dehydration. Instead, it suggested drinking plenty of water or electrolyte-filled sports drinks, using sunscreen, and wearing light-colored, loose-fitting clothing. Why It Matters According to the Centers for Disease Control and Prevention (CDC), extreme heat can lead to heat-related illnesses, especially in older adults, young children and those with chronic medical conditions. Symptoms may include heavy sweating, muscle cramps, dizziness and nausea. The CDC says more than 700 people die each year in the U.S. because of extreme heat. Additionally, rising temperatures can worsen ground-level ozone pollution, which presents additional health risks. What To Know Extreme heat warnings—which the NWS issues when "extremely dangerous heat conditions are expected or occurring"—were in place for northwest and southeast California, southern Nevada, and southwest Oregon, as well as parts of Arizona and Utah. For California and Oregon, the NWS said high temperatures in the triple digits, including up to 110 degrees in western Siskiyou County's valleys would be possible. Temperatures around 110 degrees would also be possible in Utah's lower Washington County and Zion National Park. In Arizona, the NWS said lower elevations of the Grand Canyon could see daytime temperatures up to 115 degrees, while Las Vegas, Nevada, could expect highs between 110 and 115. Death Valley, often referred to as the hottest place on Earth, was forecast to see highs between 120 and 125. Meanwhile, less severe heat advisories had been issued for parts of Washington, Idaho, Louisiana, Mississippi, Florida, and Georgia. Heat index values, which reflect how hot it feels when humidity is taken into account, could hit triple digits in many of these areas, the NWS said. What People Are Saying NWS Eureka, California said on X, Friday: "Hot temperatures are forecast for the interior in the coming days. Heat Advisories and Extreme Heat Warnings have been issued across the interior portions of the area. Slightly cooler (but still hot!) temperatures are possible by Tuesday." NWS Tallahassee, Florida said on X, Monday: "5 a.m. ET July 14, 2025: A Heat Advisory is in effect this afternoon for all of our Florida counties and portions of southern Georgia. Heat Indices are forecast to climb to between 108° to 112° in these areas with 104° to 107° elsewhere with highs between 94°-98°." What Happens Next At the time of writing, the latest extreme heat warning was in place until Wednesday evening. Regular forecast updates are issued by the NWS on its website and social media channels.
Yahoo
6 hours ago
- Yahoo
Biden's White House doctor declines to answer questions in House deposition
Former President Biden's White House doctor, Kevin O'Connor, declined to answer questions during a deposition with the House Oversight and Government Reform Committee on Wednesday, according to a statement from his legal counsel, citing physician-patient privilege and constitutional rights against self-incrimination. 'Earlier today, Dr. Kevin O'Connor asserted the physician-patient privilege, as well as his right under the Fifth Amendment to the U.S. Constitution, in declining to answer questions from the staff of the House Committee on Oversight and Government Reform regarding his service as Physician to the President during the Biden Administration,' the statement from O'Connor's legal counsel said. 'On the advice of his legal counsel, Dr. O'Connor refused to answer questions that invaded the well-established legal privilege that protects confidential matters between physicians and their patients. His assertion of his right under the Fifth Amendment to decline to answer questions, also on the advice of his lawyers, was made necessary by the unique circumstances of this deposition,' the statement said. Later in the day, the Oversight Committee released a video of the deposition, showing O'Conner identifying himself for the record, then going on to answer every question by invoking the Fifth Amendment or physician-patient privilege. He provided the same answer to both substantive questions and questions about whether he understood the proceedings. Oversight Committee Chair James Comer (R-Ky.) subpoenaed the doctor last month to compel his interview as part of the panel's investigation into Biden's mental acuity while in office and whether the 46th president was aware of documents signed with his 'autopen' signature. Comer tore into O'Conner over his refusal to answer questions. 'It's clear there was a conspiracy to cover up President Biden's cognitive decline after Dr. Kevin O'Connor, Biden's physician and family business associate, refused to answer any questions and chose to hide behind the Fifth Amendment. The American people demand transparency, but Dr. O'Connor would rather conceal the truth,' Comer said in a statement. 'Dr. O'Connor took the Fifth when asked if he was told to lie about President Biden's health and whether he was fit to be President of the United States. Congress must assess legislative solutions to prevent such a coverup from happening again. We will continue to interview more Biden White House aides to get the answers Americans deserve.' According to a written draft of a statement delivered inside the deposition room, O'Connor's lawyer, David Schertler, said the committee indicated that 'it does not intend to honor one of the most well-known privileges in our law — the physician patient privilege …. Revealing confidential patient information would violate the most fundamental ethical duty of a physician, could result in revocation of Dr. O'Connor's medical license, and would subject Dr. O'Connor to potential civil liability.' Schertler also noted President Trump has directed the Department of Justice to conduct an investigation into Biden's mental acuity while in office, arguing the Oversight panel should pause its investigation until any criminal investigation concluded. And Schertler said O'Connor's decision to assert his Fifth Amendment privilege 'does not imply that Dr. O'Connor has committed any crime.' Asked about doctor-patient confidentiality before heading into the interview, Comer told reporters: 'I don't believe that he can hide behind doctor-patient confidentiality, because this is the president of the United States, and people expect the White House physician to be truthful and transparent about the president of the United States' health.' Rep. Robert Garcia (D-Calif.), the ranking member of the committee, slammed the GOP investigation in a statement. 'The only person's health that Republicans care about is Joe Biden's – even as 17 million Americans lose access to affordable health care thanks to their big budget betrayal,' Garcia said. 'Oversight Republicans could be working to lower costs for American families and conducting oversight of President Trump's corruption, but instead are obsessed with the past. Democrats will continue to look forward and build a more effective and efficient government for the American people.' The doctor's lawyers over the weekend had requested postponement of the interview, citing concern O'Connor would not be able to protect doctor-patient privilege during the testimony, and asserting the committee had declined to rule out any limitations to the scope of the deposition. The statement from O'Connor's legal counsel referenced President Trump relying on his Fifth Amendment rights when refusing to testify in a deposition before the New York state attorney general in 2022, saying: 'Anyone in my position not taking the Fifth Amendment would be a fool — an absolute fool.' NewsNation contributed. Updated at 6:36 p.m. EDT Copyright 2025 Nexstar Media, Inc. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.
